Big Move For Vaccinex, Inc.
Vaccinex, Inc. (VCNX:NASDAQ) jumped higher at $1.13, representing a gain of 23.5%. On Thu, Jan 27, 2022, VCNX:NASDAQ hit a New 2-Week Low of $0.92. The stock got featured on our News Catalysts scanner on Fri, Jan 28, 2022 at 11:17 AM in the 'BIOTECH' category. From Fri, Jan 14, 2022, the stock recorded 25.00% Up Days and 11.11% Green Days
The stock spiked on Wed, Jan 26, 2022 at $1.28 with a volume of 42M+.
About Vaccinex, Inc. (VCNX:NASDAQ)
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.
Top 10 Gainers:
- Knightscope Inc. (KSCP:NASDAQ), 175.63%
- Option Care Health, Inc. (BIOS:NASDAQ), 100%
- Imperial Petroleum Inc. (IMPP:NASDAQ), 87.93%
- Yoshitsu Co. Ltd (TKLF:NASDAQ), 33.33%
- Advaxis, Inc. (ADXS:NASDAQ), 25.11%
- BBQ Holdings, Inc. (DAVE:NASDAQ), 23.67%
- Vaccinex, Inc. (VCNX:NASDAQ), 23.5%
- Regencell Bioscience Holdings Limited (RGC:NASDAQ), 23.35%
- Provention Bio, Inc. (PRVB:NASDAQ), 22.35%
- Rallybio Corporation (RLYB:NASDAQ), 21.54%